Irritable Bowel Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Irritable Bowel Syndrome Pipeline Drugs Market Overview
The symptoms of irritable bowel syndrome include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite, and constipation. These symptoms can be triggered by food, stress, and hormones.
The Irritable Bowel Syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects.
Irritable Bowel Syndrome Pipeline Products Market Segmentation by Targets
The key targets in the Irritable Bowel Syndrome pipeline products market are Cannabinoid Receptor 2, 5-Hydroxytryptamine Receptor 3, Cannabinoid Receptor 1, Mu Type Opioid Receptor, 5-Hydroxytryptamine Receptor 4, Kappa Type Opioid Receptor, 5-Hydroxytryptamine Receptor 2B, Bile Acid Receptor, Corticotropin Releasing Factor Receptor 1, Corticotropin Releasing Factor Receptor 2, and others.
Irritable Bowel Syndrome Pipeline Products Market Analysis by Targets
For more target insights into the Irritable Bowel Syndrome pipeline products market, download a free report sample
Irritable Bowel Syndrome Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Irritable Bowel Syndrome pipeline products market are Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Mu Type Opioid Receptor Agonist, 5-Hydroxytryptamine Receptor 3 Agonist, 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 2B Antagonist, 5-Hydroxytryptamine Receptor 3 Antagonist, Bile Acid Receptor Agonist, Corticotropin Releasing Factor Receptor 1 Antagonist, Corticotropin Releasing Factor Receptor 2 Antagonist, and others.
Irritable Bowel Syndrome Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the Irritable Bowel Syndrome pipeline products market, download a free report sample
Irritable Bowel Syndrome Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the Irritable Bowel Syndrome pipeline products market are oral and intravenous.
Irritable Bowel Syndrome Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the Irritable Bowel Syndrome pipeline products market, download a free report sample
Irritable Bowel Syndrome Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Irritable Bowel Syndrome pipeline products market are small molecule, biologic, synthetic peptide, and recombinant protein.
Irritable Bowel Syndrome Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Irritable Bowel Syndrome pipeline products market, download a free report sample
Competitive Landscape
Some of the leading players in the Irritable Bowel Syndrome pipeline products market are AbbVie Inc, ConSynance Therapeutics Inc, HK inno.N Corp, Malachite Innovations Inc, 4D Pharma Plc, Ardelyx Inc, Assembly Biosciences Inc, Bausch Health Companies Inc, Bilayer Therapeutics Inc, and Biomica.
Irritable Bowel Syndrome Pipeline Products Market Analysis by Players
To know more about the leading players in the Irritable Bowel Syndrome pipeline products market, download a free report sample
Irritable Bowel Syndrome Pipeline Products Market Report Overview
Key Targets | Cannabinoid Receptor 2, 5-Hydroxytryptamine Receptor 3, Cannabinoid Receptor 1, Mu Type Opioid Receptor, 5-Hydroxytryptamine Receptor 4, Kappa Type Opioid Receptor, 5-Hydroxytryptamine Receptor 2B, Bile Acid Receptor, Corticotropin Releasing Factor Receptor 1, Corticotropin Releasing Factor Receptor 2, and Others |
Key Mechanisms of Action | Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Mu Type Opioid Receptor Agonist, 5-Hydroxytryptamine Receptor 3 Agonist, 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 2B Antagonist, 5-Hydroxytryptamine Receptor 3 Antagonist, Bile Acid Receptor Agonist, Corticotropin Releasing Factor Receptor 1 Antagonist, Corticotropin Releasing Factor Receptor 2 Antagonist, and Others |
Key Routes of Administration | Oral and Intravenous |
Key Molecule Type | Small Molecule, Biologic, Synthetic Peptide, and Recombinant Protein |
Leading Players | AbbVie Inc, ConSynance Therapeutics Inc, HK inno.N Corp, Malachite Innovations Inc, 4D Pharma Plc, Ardelyx Inc, Assembly Biosciences Inc, Bausch Health Companies Inc, Bilayer Therapeutics Inc, and Biomica |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
AbbVie Inc
Ardelyx Inc
Assembly Biosciences Inc
Bausch Health Companies Inc
Bilayer Therapeutics Inc
Biomica
Blue Therapeutics Inc
Boston Pharmaceuticals Inc
CB2 Therapeutics Inc
CinRx Pharma LLC
ConSynance Therapeutics Inc
Cosmo Pharmaceuticals NV
Dong-A ST Co Ltd
Emyria Ltd
Exeliom Biosciences SAS
GEXVal Inc
HK inno.N Corp
ImmuneBiotech AB
Immunic Inc
Ironwood Pharmaceuticals Inc
ISOThrive Inc
Malachite Innovations Inc
Metacrine Inc
MGC Pharmaceuticals Ltd
Microba Life Sciences Ltd
Napo Pharmaceuticals Inc
Neurocrine Biosciences Inc
Nexpharm Korea Co Ltd
Novome Biotechnologies Inc
Orphomed Inc
Oxford Cannabinoid Technologies Ltd
PeptiDream Inc
Protagonist Therapeutics Inc
RaQualia Pharma Inc
RedHill Biopharma Ltd
Renexxion LLC
Seed Health Inc
Serenity Bioworks Inc
Serentrix LLC
Servatus Ltd
Shanghai Pharmaceuticals Holding Co Ltd
TenNor Therapeutics Ltd
Virios Therapeutics, Inc
Zhiyi Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Irritable Bowel Syndrome pipeline products market?
The key targets in the Irritable Bowel Syndrome pipeline products market are Cannabinoid Receptor 2, 5-Hydroxytryptamine Receptor 3, Cannabinoid Receptor 1, Mu Type Opioid Receptor, 5-Hydroxytryptamine Receptor 4, Kappa Type Opioid Receptor, 5-Hydroxytryptamine Receptor 2B, Bile Acid Receptor, Corticotropin Releasing Factor Receptor 1, Corticotropin Releasing Factor Receptor 2, and others.
-
What are the key mechanisms of action in the Irritable Bowel Syndrome pipeline products market?
The key mechanisms of action in the Irritable Bowel Syndrome pipeline products market are Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Mu Type Opioid Receptor Agonist, 5-Hydroxytryptamine Receptor 3 Agonist, 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 2B Antagonist, 5-Hydroxytryptamine Receptor 3 Antagonist, Bile Acid Receptor Agonist, Corticotropin Releasing Factor Receptor 1 Antagonist, Corticotropin Releasing Factor Receptor 2 Antagonist, and others.
-
What are the key routes of administration in the Irritable Bowel Syndrome pipeline products market?
The key routes of administration in the Irritable Bowel Syndrome pipeline products market are oral and intravenous.
-
What are the key molecule types in the Irritable Bowel Syndrome pipeline products market?
The key molecule types in the Irritable Bowel Syndrome pipeline products market are small molecule, biologic, synthetic peptide, and recombinant protein.
-
Who are the leading players in the Irritable Bowel Syndrome pipeline products market?
Some of the leading players in the Irritable Bowel Syndrome pipeline products market are AbbVie Inc, ConSynance Therapeutics Inc, HK inno.N Corp, Malachite Innovations Inc, 4D Pharma Plc, Ardelyx Inc, Assembly Biosciences Inc, Bausch Health Companies Inc, Bilayer Therapeutics Inc, and Biomica.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.